查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046416

肌萎縮側索硬化症市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、治療類型、最終用戶、地區和競爭格局分類，2021-2031年

Amyotrophic Lateral Sclerosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type (Rilutek, Edaravone ), By Treatment Type, By End-Users, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肌萎縮側索硬化症 (ALS) 市場預計將從 2025 年的 7.8781 億美元成長到 2031 年的 11.2705 億美元，複合年成長率為 6.15%。

該市場涵蓋藥物治療方法和輔助技術，旨在控制症狀並延緩這種神經退化性疾病的進展。其成長主要受以下因素驅動：患者人數因人口老化而增加，以及針對特定基因突變的精準醫療的興起。此外，科學研究的大量投資和潛在治療方法研發管線的拓展也推動了該領域的發展，例如，美國肌萎縮側索硬化症協會（ALS協會）計劃在2024年支持13個國家的149個在研項目，以加速藥物研發。

市場概覽
預測期 2027-2031
市場規模：2025年 7.8781億美元
市場規模：2031年 11.2705億美元
複合年成長率：2026-2031年 6.15%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

儘管取得了這些進展，但該行業仍面臨一項重大挑戰：候選藥物在第三期臨床試驗中的高脫落率。肌萎縮側索硬化症（ALS）複雜的生物機制常常導致在關鍵試驗階段無法確認療效，給研發人員和投資者都帶來了不確定性。這項長期挑戰將延緩監管核准，阻礙有效治療方法的推出，最終限制該領域的潛在收入來源。

市場促進因素

推動市場擴張的主要動力是公共和私人部門對研發投入的不斷成長，而這又源於對有效緩解疾病治療方法的迫切需求。這些資金的湧入對於支付臨床試驗的巨額成本以及推進候選療法從早期發現階段走向商業化至關重要。例如，2024年11月，Trace Neuroscience獲得了1.01億美元的投資，用於將其針對神經退化性疾病的基因組療法推進臨床試驗。同樣，非營利組織在降低早期科學探索風險方面也發揮關鍵作用。 FightMND於2024年11月宣布追加1,889萬美元的資金，用於其研究和護理工作，凸顯了全球為克服療效障礙而進行的巨額投資。

第二個關鍵驅動力是基因研究和精準醫學的進步。這些進步從根本上改變了產業的重心，使其從症狀管理轉向靶向生物干預。例如，識別特定突變（如SOD1基因突變）使得開發針對疾病根本原因的反義寡核苷酸成為可能。這項進步使得開展更具分層性的臨床試驗成為可能，透過在最有可能產生療效的病患小組中測試治療方法，有望降低失敗率。例如，2024年5月，LifeArc承諾向一項旨在檢驗人類基因治療標靶的新夥伴關係投入150萬英鎊。此舉旨在彌合藥物研發中的轉換鴻溝，並吸引相關人員關注個人化解決方案。

市場挑戰

治療候選化合物在臨床開發後期階段的高脫落率是全球ALS市場成長的主要障礙。這個難題主要源自於疾病的複雜性和異質性，使得尋找可靠的生物標記來評估藥物療效變得困難。因此，當前景看好的早期化合物在III期主要試驗中未能展現出統計學意義上的顯著療效時，製藥公司往往會遭遇挫折。這些後期失敗會導致臨床開發成本呈指數級成長，從而造成巨大的經濟損失，進而疏遠風險規避型投資者，並減少未來科學研究所需的資金流入。

這一連串失敗直接阻礙了市場擴張，導致有效治療方法的商業化進程延緩，產品平臺出現瓶頸。監管核准的不確定性迫使研發人員延長研發週期，大幅增加研發預算，降低了潛在利潤率，並限制了最終能夠上市的成功案例數量。據美國肌萎縮側索硬化症協會（ALS Association）稱，到2025年，將有超過50種針對不同作用機制的ALS療法正在研發中，但由於該行業長期以來難以將這些候選藥物轉化為核准治療方法，因此只有少數療法真正能夠盈利，這直接阻礙了該行業的財務發展。

市場趨勢

人工智慧 (AI) 和機器學習 (ML) 的融合正在革新新型治療標靶的發現，並有效應對複雜疾病生物學帶來的挑戰。透過分析龐大的基因組資料集，這些平台能夠比傳統動物模型更準確地預測因果機制，從而簡化發現過程。這種方法利用 AI 驅動的檢驗來降低臨床試驗開始前候選化合物選擇的風險，確保資源投入最有可能成功的化合物。例如，Verge Genomics 在 2024 年 11 月報告稱，其 AI 驅動的平台在疾病相關模型中對優先靶點的檢驗率達到了 83%，顯著超過了行業基準。

同時，神經絲輕鏈 (NfL) 生物標記的引入，透過提供疾病監測的客觀標準，正在改變臨床試驗的設計。與主觀的功能評估方法不同，NfL 水平能夠定量反映神經軸突損傷程度，使研究人員能夠更快、更準確地檢測患者對治療的反應。這種調查方法透過加快藥物研發決策和支持患者群體分層，提高了試驗的有效性。正如《ALS News Today》2024 年 7 月報道，血液 NfL 水平已被證實能夠準確識別約 80% 的 ALS 患者，在疾病鑑別診斷方面顯著優於其他潛在的蛋白質標誌物。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球肌萎縮側索硬化症（ALS）市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物類型（力如太（Riluzole）、Edaravone（Radicaba））
    • 治療方法（物理治療、語言治療、藥物治療、呼吸治療等）
    • 依最終使用者（醫院/診所、研究/學術機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肌萎縮側索硬化症（ALS）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肌萎縮側索硬化症（ALS）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肌萎縮側索硬化症（ALS）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肌萎縮側索硬化症（ALS）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美肌萎縮側索硬化症（ALS）市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球肌萎縮側索硬化症（ALS）市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Sanofi SA
  • Brainstorm Cell Therapeutics Inc.
  • Biogen Inc.
  • Bausch Health Cos Inc.
  • F Hoffmann-la Roche Ltd
  • Ionis Pharmaceuticals
  • Mylan Pharma Inc.
  • Sun Pharmaceutical Industries Inc
  • Orion Pharma A/S
  • AB Science SA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19774

The Global Amyotrophic Lateral Sclerosis (ALS) Market is projected to expand from USD 787.81 Million in 2025 to USD 1127.05 Million by 2031, reflecting a CAGR of 6.15%. This market encompasses both pharmaceutical therapeutics and assistive technologies designed to manage symptoms and slow the progression of this neurodegenerative disorder. Growth is primarily propelled by an increasing prevalence of the condition within an aging demographic and the rise of precision medicine targeting specific genetic mutations. Furthermore, the sector is bolstered by significant investments in scientific research and a widening pipeline of potential treatments, evidenced by the ALS Association supporting 149 active research projects across 13 countries in 2024 to speed up drug development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 787.81 Million
Market Size 2031USD 1127.05 Million
CAGR 2026-20316.15%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Despite these advancements, the industry faces a significant hurdle due to the high attrition rate of candidates during advanced clinical trials. The intricate biological mechanisms of ALS often lead to efficacy failures in pivotal testing stages, generating uncertainty for both developers and investors. This enduring challenge postpones regulatory approvals and hinders the launch of effective therapeutic alternatives, thereby constraining potential revenue streams within the sector.

Market Driver

A major catalyst for market expansion is the escalating public and private investment in research and development, driven by the urgent need for effective disease-modifying treatments. This financial influx is essential for covering the substantial costs of clinical trials and supporting the progression of therapeutic candidates from early discovery to commercial viability. For example, in November 2024, Trace Neuroscience secured a $101 million investment to advance genomic therapies for neurodegenerative conditions into clinical phases. Similarly, the non-profit sector is crucial in de-risking early scientific exploration, as demonstrated by FightMND's commitment of an additional $18.89 million to research and care initiatives in November 2024, highlighting the strong global funding dedicated to overcoming efficacy barriers.

The second significant driver is the advancement in genetic research and precision medicine, which is fundamentally altering the industry's focus from symptom management to targeted biological interventions. Identifying specific mutations, such as those in the SOD1 gene, has facilitated the creation of antisense oligonucleotides that target the disorder's root causes. This progress enables more stratified clinical trials, potentially lowering failure rates by testing therapies on the most responsive patient groups. Illustrating this shift, LifeArc pledged £1.5 million in May 2024 to a new partnership focused on validating human genetic therapeutic targets, thereby aiming to bridge the translational gap in drug development and attract stakeholder interest in personalized solutions.

Market Challenge

The substantial attrition rate of therapeutic candidates during advanced clinical phases acts as a major barrier to the Global ALS Market's growth. This difficulty largely arises from the disease's complex and heterogeneous nature, which complicates the identification of robust biological markers for assessing drug efficacy. As a result, pharmaceutical companies often face setbacks when promising early-stage compounds fail to show statistically significant benefits in pivotal Phase III trials. These late-stage failures result in considerable financial losses due to the exponentially increasing costs of clinical development, which in turn discourages risk-averse investors and diminishes the capital inflow needed for future scientific pursuits.

This continuous cycle of failure directly limits market expansion by postponing the commercialization of viable treatments and causing bottlenecks in the product pipeline. The unpredictability regarding regulatory approval compels developers to prolong timelines and drastically raise research budgets, eroding potential profit margins and restricting the number of successful market entrants. According to the ALS Association, although there were more than 50 ALS drugs targeting various mechanisms under development in 2025, the industry's historical struggle to translate these candidates into approved therapies means the actual introduction of revenue-generating options remains minimal, directly impeding the sector's financial progress.

Market Trends

The integration of Artificial Intelligence (AI) and Machine Learning (ML) is revolutionizing the discovery of novel therapeutic targets, effectively addressing the challenges posed by complex disease biology. By analyzing extensive genomic datasets, these platforms can predict causal mechanisms with greater precision than traditional animal models, thereby streamlining the discovery process. This approach utilizes AI-driven validation to de-risk candidate selection prior to clinical entry, ensuring that resources are directed toward compounds with the highest likelihood of success. For instance, Verge Genomics reported in November 2024 that its AI-enabled platform achieved an 83% validation rate for prioritized targets in disease-relevant models, significantly surpassing standard industry benchmarks.

Simultaneously, the incorporation of Neurofilament Light Chain (NfL) biomarkers is transforming clinical trial designs by providing an objective standard for disease monitoring. In contrast to subjective functional rating scales, NfL levels deliver a quantifiable measure of neuroaxonal damage, allowing researchers to detect patient responses to treatment with greater speed and accuracy. This methodology facilitates earlier decision-making in drug development and aids in stratifying patient populations to improve trial efficacy. As highlighted by ALS News Today in July 2024, blood-based NfL levels demonstrated the ability to accurately identify approximately 80% of ALS patients, significantly outperforming other potential protein markers in distinguishing the condition.

Key Market Players

  • Sanofi S.A.
  • Brainstorm Cell Therapeutics Inc.
  • Biogen Inc.
  • Bausch Health Cos Inc.
  • F Hoffmann-la Roche Ltd
  • Ionis Pharmaceuticals
  • Mylan Pharma Inc.
  • Sun Pharmaceutical Industries Inc
  • Orion Pharma A/S
  • AB Science SA

Report Scope

In this report, the Global Amyotrophic Lateral Sclerosis (ALS) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amyotrophic Lateral Sclerosis (ALS) Market, By Drug Type

  • Rilutek (Riluzole)
  • Edaravone (Radicava)

Amyotrophic Lateral Sclerosis (ALS) Market, By Treatment Type

  • Physical Therapy
  • Speech Therapy
  • Medication
  • Respiratory Therapy
  • Others

Amyotrophic Lateral Sclerosis (ALS) Market, By End-Users

  • Hospitals & Clinics
  • Research and Academic institutes
  • others

Amyotrophic Lateral Sclerosis (ALS) Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amyotrophic Lateral Sclerosis (ALS) Market.

Available Customizations:

Global Amyotrophic Lateral Sclerosis (ALS) Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Amyotrophic Lateral Sclerosis (ALS) Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type (Rilutek (Riluzole), Edaravone (Radicava))
    • 5.2.2. By Treatment Type (Physical Therapy, Speech Therapy, Medication, Respiratory Therapy, Others)
    • 5.2.3. By End-Users (Hospitals & Clinics, Research and Academic institutes, others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Amyotrophic Lateral Sclerosis (ALS) Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By End-Users
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Treatment Type
        • 6.3.1.2.3. By End-Users
    • 6.3.2. Canada Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Treatment Type
        • 6.3.2.2.3. By End-Users
    • 6.3.3. Mexico Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Treatment Type
        • 6.3.3.2.3. By End-Users

7. Europe Amyotrophic Lateral Sclerosis (ALS) Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By End-Users
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By End-Users
    • 7.3.2. France Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By End-Users
    • 7.3.3. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By End-Users
    • 7.3.4. Italy Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Type
        • 7.3.4.2.2. By Treatment Type
        • 7.3.4.2.3. By End-Users
    • 7.3.5. Spain Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Type
        • 7.3.5.2.2. By Treatment Type
        • 7.3.5.2.3. By End-Users

8. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By End-Users
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By End-Users
    • 8.3.2. India Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By End-Users
    • 8.3.3. Japan Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By End-Users
    • 8.3.4. South Korea Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Type
        • 8.3.4.2.2. By Treatment Type
        • 8.3.4.2.3. By End-Users
    • 8.3.5. Australia Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Type
        • 8.3.5.2.2. By Treatment Type
        • 8.3.5.2.3. By End-Users

9. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By End-Users
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By End-Users
    • 9.3.2. UAE Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By End-Users
    • 9.3.3. South Africa Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By End-Users

10. South America Amyotrophic Lateral Sclerosis (ALS) Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By End-Users
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Type
        • 10.3.1.2.2. By Treatment Type
        • 10.3.1.2.3. By End-Users
    • 10.3.2. Colombia Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Type
        • 10.3.2.2.2. By Treatment Type
        • 10.3.2.2.3. By End-Users
    • 10.3.3. Argentina Amyotrophic Lateral Sclerosis (ALS) Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Type
        • 10.3.3.2.2. By Treatment Type
        • 10.3.3.2.3. By End-Users

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Amyotrophic Lateral Sclerosis (ALS) Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sanofi S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Brainstorm Cell Therapeutics Inc.
  • 15.3. Biogen Inc.
  • 15.4. Bausch Health Cos Inc.
  • 15.5. F Hoffmann-la Roche Ltd
  • 15.6. Ionis Pharmaceuticals
  • 15.7. Mylan Pharma Inc.
  • 15.8. Sun Pharmaceutical Industries Inc
  • 15.9. Orion Pharma A/S
  • 15.10. AB Science SA

16. Strategic Recommendations

17. About Us & Disclaimer